Brain Health & Nootropics
Ara-290
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Neural Repair
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10, 30 mg
Dosing window: Anytime
Receptor / target: Innate Repair Receptor
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 4mg daily | Consistent daily dosing required for continuous nerve regeneration. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 2 mg 1x Daily | Initiation phase. |
| Weeks 2-12 | 4 mg 1x Daily | 12 weeks on, 6 week washout. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 8 mg 1x Daily | Aggressive protocol. Maximum 4 weeks. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (Innate Repair Receptor); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Known hypersensitivity to ARA-290, EPO-derived peptides, or formulation excipients. Limited / unverified
- Active malignancy with EPO receptor expression: while ARA-290 does not drive erythropoiesis, certain tumors express IRR components (βcR) and could theoretically receive pro-survival IRR signaling; caution in oncological contexts. Limited / unverified
- Concurrent full-dose EPO administration: ARA-290 and EPO may compete at the EPOR/βcR receptor complex; combined use is not characterized. Limited / unverified
- Pregnancy: IRR signaling in fetal tissue development is not characterized; safety not established. Limited / unverified
- Breastfeeding: no safety data. Limited / unverified
- Pediatric use: no safety or dosing data established. Limited / unverified
- Autoimmune conditions currently treated with immunosuppressive biologics: ARA-290's immunomodulatory activity may interact unpredictably with concurrent biologic immunosuppression. Limited / unverified
Side effects (limited evidence)
- Mild injection site irritation: the most consistently reported adverse effect; localized redness, mild tenderness, and minor swelling at the subcutaneous injection site; mild and self-resolving; standard for subcutaneous peptide administration. Limited / unverified
- Mild transient fatigue: reported in a subset of subjects during the first week; possibly related to the acute neuroinflammatory modulation phase. Limited / unverified
- Mild headache: uncommon; transient; mechanism not characterized. Limited / unverified
- Transient dizziness: rare; mild; possibly related to βcR-mediated vasodilatory activity in some subjects. Limited / unverified
- Nausea: uncommon; mild; self-limiting. Limited / unverified
- No erythropoietic effects: ARA-290 has no meaningful activity at the classical EPOR homodimer that drives red blood cell production; hematocrit and hemoglobin are not elevated; there is no thrombotic or polycythemia risk. Limited / unverified
- No hormonal disruption: ARA-290 has no activity at endocrine receptors; does not affect the HPA axis, sex hormones, thyroid, or IGF-1 axis. Limited / unverified
- Potential IRR desensitization with continuous long-term use: not documented but theoretically possible with extended uninterrupted administration; the washout protocol mitigates this. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.